Search

Your search keyword '"Amylou C. Dueck"' showing total 781 results

Search Constraints

Start Over You searched for: "Amylou C. Dueck" Remove constraint "Amylou C. Dueck"
781 results on '"Amylou C. Dueck"'

Search Results

201. Patient-Reported Symptomatic Adverse Events (PRO-CTCAE) during Proton and Photon Radiation Therapy: Results of a Prospective Registry of Patient-Reported Outcomes in a Large-Volume, Multi-Site Practice

202. PF675 JAK2V617F AND MPL MUTATIONS ARE ASSOCIATED WITH WORSENED SYMPTOM BURDEN THAN CALR IN THE MYELOPROLIFERATIVE NEOPLASMS: FINDINGS FROM THE MYMPN PATIENT REGISTRY

203. PS1501 QUALITY OF LIFE IN PATIENTS UNDERGOING CHIMERIC ANTIGEN RECEPTOR (CAR) - T CELL THERAPY VS. AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANT FOR HEMATOLOGIC MALIGNANCIES

204. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

205. The relationship among gastroparetic symptoms, quality of life, and gastric emptying in patients referred for gastric emptying testing

206. Psychological distress in Rome III functional dyspepsia patients presenting for testing of gastric emptying

207. Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls

208. Rates of residual disease with close but negative margins in breast cancer surgery

209. Validation of a gastric cancer nomogram using a cancer registry

210. Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis

211. Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast

212. Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)

213. Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial

214. Quality of life and disease understanding: impact of attending a patient‐centered cancer symposium

215. Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development

216. Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial

217. NIMG-74. RADIOMICS OF TUMOR INVASION 2.0: COMBINING MECHANISTIC TUMOR INVASION MODELS WITH MACHINE LEARNING MODELS TO ACCURATELY PREDICT TUMOR INVASION IN HUMAN GLIOBLASTOMA PATIENTS

218. Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms

219. Optimization of DSC-MRI Echo Times for CBV Measurements using Error Analysis in a Pilot Study of High-Grade Gliomas

220. Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement

221. Determination of mild, moderate, and severe pain interference in patients with cancer

222. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia

223. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs

224. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial

225. Feasibility assessment of patient reporting of symptomatic adverse events in multicenter cancer clinical trials

226. Public Perceptions of Presymptomatic Testing for Alzheimer Disease

227. Implications of breast cancer with diabetes mellitus on patient outcomes and care

229. Expansion of Prior Existing TP53 Mutated Clones in Polycythemia Vera Patients Treated with Idasanutlin

230. Significance of Abnormalities of PPM1D in Myeloproliferative Neoplasms

231. A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

232. Patient Experience of Chimeric Antigen Receptor (CAR)-T Cell Therapy Vs. Stem Cell Transplant: Longitudinal Patient Reported Adverse Events, Cognition and Quality of Life

233. Identifying Cytokine Biomarkers of Response to Pegylated-Interferon Therapy in Polycythemia Vera and Essential Thrombocythemia: Correlative Analysis from the MPN-RC 111/112 Trials

234. Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Settings

235. PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS

236. Evaluation of minimal important difference (MID) for the European organisation for research and treatment of cancer (EORTC) pancreatic cancer module (PAN26) in patients with surgically resected pancreatic adenocarcinoma

237. Radiation Therapy Treatment Effect on Overall Survival: Results of a Prospective Registry of Patient-Reported Outcomes in a Large-Volume Multi-Site Practice

238. P1-480: APOE-DEPENDENT VERBAL LEARNING EFFECTS IN COGNITIVELY UNIMPAIRED OLDER ADULTS

239. Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT)

240. Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians

241. Treatment completion and toxicity of trastuzumab or trastuzumab + lapatinib in older patients (pts): BIG 2-06; NCCTG N063D (Alliance)

242. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502)

243. Longitudinal toxicity analysis with novel summary metrics of lenalidomide maintenance in follicular lymphoma in ECOG-ACRIN 2408

244. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma

245. Predictive Testing for Alzheimer’s Disease

246. Depressive Symptoms in Healthy Apolipoprotein E ε4 Carriers and Noncarriers

247. Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch

248. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from North Central Cancer Treatment Group adjuvant trial N9831

249. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

250. Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: The mayo clinic arizona experience

Catalog

Books, media, physical & digital resources